Data from an on-going phase II trial of the AE37 breast cancer vaccine correlated local immune response to a reduction in relapse.
How’s this for a paradox: The better cancer centers become at keeping patients alive, the more expensive cancer care becomes. This brutal tradeoff hits harder in rural areas, where the cancer burden is higher and the investigator and clinical trial representation is lower.
